Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria

Limited treatment options are among the main reasons why antimicrobial resistance has become a leading major public health problem. In particular, carbapenem-resistant <i>Enterobacteriales</i> (CRE), <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>...

Full description

Bibliographic Details
Main Authors:	Marta Palombo, Federica Bovo, Stefano Amadesi, Paolo Gaibani
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Antibiotics
Subjects:	antimicrobial resistance (AMR) carbapenem-resistant bacteria gram-negative bacteria cefiderocol synergy
Online Access:	https://www.mdpi.com/2079-6382/12/5/858

Similar Items

In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/ aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
by: Kalyani Borde, et al.
Published: (2023-10-01)

In Vitro Susceptibility of <i>Burkholderia pseudomallei</i> Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India
by: Jayanti Jena, et al.
Published: (2023-12-01)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
by: Paolo Gaibani, et al.
Published: (2022-05-01)

Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient
by: Paolo Gaibani, et al.
Published: (2022-09-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

The solution to drug resistance of Gram-negative bacteria – Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023-05-01)

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
by: Braulio Josué Méndez-Sotelo, et al.
Published: (2024-01-01)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022-12-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
by: Caterina Ferretti, et al.
Published: (2024-06-01)

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
by: Dee Shortridge, et al.
Published: (2022-04-01)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022-12-01)

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany
by: Philipp Thelen, et al.
Published: (2022-03-01)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023-05-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
by: Silvia Corcione, et al.
Published: (2022-09-01)

Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms
by: Jiahui Yao, et al.
Published: (2021-12-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against <i>KPC</i>-Producing <i>K. pneumoniae</i> Collected from Bacteremic Patients, 2018 to 2020
by: Federica Bovo, et al.
Published: (2022-11-01)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain
by: Emilia Cercenado, et al.
Published: (2021-09-01)

Electrochemical detection of cefiderocol for therapeutic drug monitoring
by: James McLeod, et al.
Published: (2021-12-01)

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
by: Chuanhai Wang, et al.
Published: (2022-04-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
by: Frontiers Production Office
Published: (2022-08-01)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Arta Karruli, et al.
Published: (2023-12-01)

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185
by: Akito Kawai, et al.
Published: (2024-02-01)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
by: Rémy A. Bonnin, et al.
Published: (2023-01-01)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022-05-01)

Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping
by: Juan Antonio Castillo-Polo, et al.
Published: (2024-04-01)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023-03-01)

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
by: Sara Domingues, et al.
Published: (2023-06-01)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing <i>Klebsiella pneumoniae</i>
by: Federica Bovo, et al.
Published: (2023-03-01)

Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
by: Ángel Marcos Fendian, et al.
Published: (2023-03-01)

Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
by: Pierluigi Viale, et al.
Published: (2023-06-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
by: Gabriele Palermo, et al.
Published: (2023-04-01)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019-05-01)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019-05-01)

Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement
by: Andrea Cortegiani, et al.
Published: (2022-07-01)